Valuation: Orion Oyj

Market Cap 1.14TCr 1.31TCr 1.06TCr 973.81Cr 1.84TCr 1,25100Cr 1.87TCr 13TCr 4.91TCr 62TCr 4.92TCr 4.81TCr 2,08900Cr P/E 2026 *
20.1x
P/E 2027 * 17.3x
Enterprise Value 1.13TCr 1.3TCr 1.05TCr 964.64Cr 1.82TCr 1,24000Cr 1.85TCr 12TCr 4.86TCr 62TCr 4.88TCr 4.77TCr 2,06900Cr EV / Sales 2026 *
5.39x
EV / Sales 2027 * 4.68x
Free-Float
90.5%
Yield 2026 *
2.39%
Yield 2027 * 2.67%
1 day+4.81%
6 months+1.78%
Current year+1.78%
Current year 78.95
Extreme 78.95
82.75
1 year 78.95
Extreme 78.95
82.75
3 years 37
Extreme 37
82.75
5 years 37
Extreme 37
82.75
10 years 27.35
Extreme 27.35
82.75
Manager TitleAgeSince
Chief Executive Officer 59 01/11/2022
Director of Finance/CFO 50 01/05/2024
Chief Operating Officer 46 01/01/2022
Director TitleAgeSince
Director/Board Member 63 22/03/2017
Director/Board Member 65 22/03/2017
Director/Board Member 66 06/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
+4.81%-.--% - - 1.31TCr
-0.92%-4.27%+54.72%+151.90% 1,03000Cr
+0.88%-2.08%+56.56%+53.95% 62TCr
-2.22%-3.07%+33.00%+68.07% 45TCr
+0.06%-0.42%+37.53%+30.67% 35TCr
-0.14%-0.24%+34.41%+39.01% 30TCr
-0.69%-0.30%+11.55%+12.93% 27TCr
-7.37%-4.40%-2.54%-43.87% 23TCr
-0.32%+2.57%+30.71%+64.73% 21TCr
-0.40%+0.94%+16.23%+71.42% 16TCr
Average -0.58%+4.83%+30.24%+49.87% 40.14TCr
Weighted average by Cap. -0.88%+4.87%+39.08%+72.46%

Financials

2026 *2027 *
Net sales 209.44Cr 240.93Cr 194.94Cr 178.98Cr 337.99Cr 23TCr 343.23Cr 2.3TCr 901.84Cr 11TCr 904.83Cr 884.95Cr 38TCr 235.39Cr 270.79Cr 219.1Cr 201.16Cr 379.88Cr 26TCr 385.76Cr 2.58TCr 1.01TCr 13TCr 1.02TCr 994.62Cr 43TCr
Net income 57Cr 65Cr 53Cr 48Cr 91Cr 6.21TCr 93Cr 620.71Cr 243.61Cr 3.09TCr 244.42Cr 239.05Cr 10TCr 65Cr 75Cr 61Cr 56Cr 105.06Cr 7.15TCr 106.69Cr 714.25Cr 280.32Cr 3.56TCr 281.25Cr 275.07Cr 12TCr
Net Debt -11Cr -12Cr -9.98Cr -9.17Cr -17Cr -1.18TCr -18Cr -117.67Cr -46Cr -586.33Cr -46Cr -45Cr -1.97TCr -37Cr -42Cr -34Cr -32Cr -59Cr -4.05TCr -60Cr -404.47Cr -158.74Cr -2.02TCr -159.27Cr -155.77Cr -6.76TCr
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,000
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
80.95EUR
Average target price
76.50EUR
Spread / Average Target
-5.50%

Quarterly revenue - Rate of surprise